729 related articles for article (PubMed ID: 27575852)
1. Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.
de Souza AL; Marra K; Gunn J; Samkoe KS; Kanick SC; Davis SC; Chapman MS; Maytin EV; Hasan T; Pogue BW
Br J Cancer; 2016 Sep; 115(7):805-13. PubMed ID: 27575852
[TBL] [Abstract][Full Text] [Related]
2. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
Choudry K; Brooke RC; Farrar W; Rhodes LE
Br J Dermatol; 2003 Jul; 149(1):124-30. PubMed ID: 12890205
[TBL] [Abstract][Full Text] [Related]
3. Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell lines.
Yang J; Xia Y; Liu X; Jiang S; Xiong L
Lasers Med Sci; 2010 Mar; 25(2):251-7. PubMed ID: 19705180
[TBL] [Abstract][Full Text] [Related]
4. The effect of light fractionation with a 2-h dark interval on the efficacy of topical hexyl-aminolevulinate photodynamic therapy in normal mouse skin.
Middelburg TA; de Bruijn HS; van der Ploeg-van den Heuvel A; Neumann HA; Robinson DJ
Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):703-9. PubMed ID: 24284130
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer.
Fukuhara H; Inoue K; Kurabayashi A; Furihata M; Fujita H; Utsumi K; Sasaki J; Shuin T
Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):399-409. PubMed ID: 24284092
[TBL] [Abstract][Full Text] [Related]
6. Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin.
de Bruijn HS; Brooks S; van der Ploeg-van den Heuvel A; Ten Hagen TL; de Haas ER; Robinson DJ
PLoS One; 2016; 11(2):e0148850. PubMed ID: 26872051
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of photodynamic therapy in gastric cancer cells by removal of iron.
Tan WC; Krasner N; O'Toole P; Lombard M
Gut; 1997 Jul; 41(1):14-8. PubMed ID: 9274465
[TBL] [Abstract][Full Text] [Related]
8. Improvement of the efficacy of 5-aminolevulinic acid-mediated photodynamic treatment in human oral squamous cell carcinoma HSC-4.
Yamamoto M; Fujita H; Katase N; Inoue K; Nagatsuka H; Utsumi K; Sasaki J; Ohuchi H
Acta Med Okayama; 2013; 67(3):153-64. PubMed ID: 23804138
[TBL] [Abstract][Full Text] [Related]
9. Microscopic distribution of protoporphyrin (PpIX) fluorescence in superficial basal cell carcinoma during light-fractionated aminolaevulinic acid photodynamic therapy.
de Haas ER; de Bruijn HS; Sterenborg HJ; Neumann HA; Robinson DJ
Acta Derm Venereol; 2008; 88(6):547-54. PubMed ID: 19002337
[TBL] [Abstract][Full Text] [Related]
10. Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine.
Palasuberniam P; Kraus D; Mansi M; Braun A; Howley R; Myers KA; Chen B
Photochem Photobiol; 2019 Jul; 95(4):1052-1059. PubMed ID: 30767226
[TBL] [Abstract][Full Text] [Related]
11. Desferrioxamine Enhances 5-Aminolaevulinic Acid- Induced Protoporphyrin IX Accumulation and Therapeutic Efficacy for Hypertrophic Scar.
Chen Y; Deng H; Yang L; Guo L; Feng M
J Pharm Sci; 2023 Jun; 112(6):1635-1643. PubMed ID: 36682488
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Kanick SC; Davis SC; Zhao Y; Sheehan KL; Hasan T; Maytin EV; Pogue BW; Chapman MS
Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):561-6. PubMed ID: 26480810
[TBL] [Abstract][Full Text] [Related]
13. In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an erbium:YAG laser.
Shen SC; Lee WR; Fang YP; Hu CH; Fang JY
J Pharm Sci; 2006 Apr; 95(4):929-38. PubMed ID: 16493590
[TBL] [Abstract][Full Text] [Related]
14. Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors.
Curnow A; Pye A
J Environ Pathol Toxicol Oncol; 2007; 26(2):89-103. PubMed ID: 17725535
[TBL] [Abstract][Full Text] [Related]
15. The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions.
Blake E; Allen J; Curnow A
Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):575-82. PubMed ID: 24284114
[TBL] [Abstract][Full Text] [Related]
16. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations.
Wiegell SR; Fabricius S; Heydenreich J; Enk CD; Rosso S; Bäumler W; Baldursson BT; Wulf HC
Br J Dermatol; 2013 Jan; 168(1):186-91. PubMed ID: 22860885
[TBL] [Abstract][Full Text] [Related]
17. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo.
Anand S; Honari G; Hasan T; Elson P; Maytin EV
Clin Cancer Res; 2009 May; 15(10):3333-43. PubMed ID: 19447864
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy of human Barrett's cancer using 5-aminolaevulinic acid-induced protoporphyrin IX: an in-vivo dosimetry study in athymic nude mice.
Pech O; Nagy CD; Gossner L; May A; Ell C
Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):657-62. PubMed ID: 12072600
[TBL] [Abstract][Full Text] [Related]
19. In vitro/in vivo correlations between transdermal delivery of 5-aminolaevulinic acid and cutaneous protoporphyrin IX accumulation and effect of formulation.
Tsai JC; Chen IH; Wong TW; Lo YL
Br J Dermatol; 2002 May; 146(5):853-62. PubMed ID: 12000384
[TBL] [Abstract][Full Text] [Related]
20. An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.
Anayo L; Magnussen A; Perry A; Wood M; Curnow A
Lasers Surg Med; 2018 Jul; 50(5):552-565. PubMed ID: 29603761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
